Advertisement

The antiobese effect of AT1 receptor blockade is augmented in mice lacking Mas

  • Carla Dapper
  • Franziska Schuster
  • Ines Stölting
  • Florian Vogt
  • Lucas Araújo Castro e Souza
  • Natalia Alenina
  • Michael Bader
  • Walter RaaschEmail author
Original Article
  • 25 Downloads

Abstract

We recently showed that the antiobese efficacy of the AT1 receptor blocker telmisartan (TEL) is at least partially related to an Ang(1-7)-dependent mechanism. Ang(1-7) acts via Mas, thus raising the question of whether Mas-deficient (Mas-ko) mice are likewise predisposed to develop diet-induced obesity and, further, whether this can be prevented by TEL treatment. Mas-ko mice and FVB/N wild-type (wt) animals were treated with TEL (8 mg/kg/day) or vehicle while they were fed with high-fat diet (HFD) or chow. Mice were phenotyped regarding body weight, fat mass, insulin sensitivity, and leptin sensitivity. In response to HFD feeding, gain in body weight and impairment of leptin sensitivity were similar between wt and Mas-ko mice. TEL reduced body weight in both strains but effects were stronger in Mas-ko mice. TEL diminished fat mass and restored leptin sensitivity only in Mas-ko mice. Blood glucose was higher in wt than Mas-ko mice fed with HFD while not differing when they were fed with chow. Insulin challenge confirmed that wt mice became insulin resistant when fed with HFD while HFD feeding did not impair insulin sensitivity in Mas-ko mice. TEL had no further effect. Our findings on the influence of TEL on growth and metabolism in Mas-ko mice conflict with our previous findings in rats. We assume that the FVB/N background of the mice may partly explain these inconsistent data. Moreover, it also seems feasible that the MrgD receptor compensates for Mas deficiency.

Keywords

Angiotensins Antiobese Mas-ko mice 

Notes

Acknowledgments

We thank Prof. Marcus Altfeld and Urte Matschl from the Heinrich Pette Institute, Hamburg, for the measurements with the luminex system. The authors gratefully acknowledge Sherryl Sundell for improving the English style.

Author contributions

CD, FS, IS, FV, NA, and LACS performed the research; WR, MB, and CD designed the research study; CD, FS, FV, NA, LACS, and WR analyzed the data; WR, MB, and CD wrote the paper.

Funding information

Carla Dapper and Franziska Schuster were supported by a grant of the German Research Foundation to the Graduiertenkolleg 1957 “Adipocyte-Brain Crosstalk,” University of Lübeck. The study was supported by a grant of the German Centre for Cardiovascular Research (DZHK). Walter Raasch received Telmisartan from Boehringer Ingelheim Pharmaceuticals, Inc. (Ingelheim, Germany).

Compliance with ethical standards

All animal care and experimental procedures were in accordance with the NIH guidelines for the care and use of laboratory animals and were approved by the animal ethics committee of the local regulatory authority (Ministerium für Energiewende, Landwirtschaft, Umwelt, Natur und Digitalisierungdes Bundeslandes Schleswig-Holstein).

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

210_2019_1643_MOESM1_ESM.docx (357 kb)
ESM 1 (DOCX 356 kb)

References

  1. Bader M (2013) ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pflugers Arch 465:79–85CrossRefGoogle Scholar
  2. Bharadwaj MS et al (2011) Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 58:852–858.  https://doi.org/10.1161/hypertensionaha.111.179358 CrossRefGoogle Scholar
  3. Blanke K, Schlegel F, Raasch W, Bader M, Dahnert I, Dhein S, Salameh A (2015) Effect of angiotensin(1-7) on heart function in an experimental rat model of obesity. Front Physiol 6:392.  https://doi.org/10.3389/fphys.2015.00392 CrossRefGoogle Scholar
  4. Bosnyak S, Widdop RE, Denton KM, Jones ES (2012) Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens 2012:192567.  https://doi.org/10.1155/2012/192567 CrossRefGoogle Scholar
  5. Botelho-Santos GA, Bader M, Alenina N, Santos RA (2012) Altered regional blood flow distribution in Mas-deficient mice. Ther Adv Cardiovasc Dis 6:201–211.  https://doi.org/10.1177/1753944712461164 CrossRefGoogle Scholar
  6. Chin SH et al (2015) Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice. Diabetes 64:1131–1141.  https://doi.org/10.2337/db14-0779 CrossRefGoogle Scholar
  7. Choi MS, Kim YJ, Kwon EY, Ryoo JY, Kim SR, Jung UJ (2015) High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes. Br J Nutr 113:867–877.  https://doi.org/10.1017/s0007114515000100 CrossRefGoogle Scholar
  8. Collister JP, Hendel MD (2003) The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin-Angiotensin-Aldosterone Syst 4:176–179.  https://doi.org/10.3317/jraas.2003.028 CrossRefGoogle Scholar
  9. Colombo C, Haluzik M, Cutson JJ, Dietz KR, Marcus-Samuels B, Vinson C, Gavrilova O, Reitman ML (2003) Opposite effects of background genotype on muscle and liver insulin sensitivity of lipoatrophic mice. Role of triglyceride clearance. J Biol Chem 278:3992–3999.  https://doi.org/10.1074/jbc.M207665200 CrossRefGoogle Scholar
  10. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al (2015) Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172:3461–3471Google Scholar
  11. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, Smith JD (1999) Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:1960–1968CrossRefGoogle Scholar
  12. de Moura MM, dos Santos RA, Campagnole-Santos MJ, Todiras M, Bader M, Alenina N, Haibara AS (2010) Altered cardiovascular reflexes responses in conscious angiotensin-(1-7) receptor Mas-knockout mice. Peptides 31:1934–1939.  https://doi.org/10.1016/j.peptides.2010.06.030 CrossRefGoogle Scholar
  13. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ (2001) A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 106:619–632CrossRefGoogle Scholar
  14. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE (1987) A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 120:2334–2338.  https://doi.org/10.1210/endo-120-6-2334 CrossRefGoogle Scholar
  15. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 288:1027–1031.  https://doi.org/10.1006/bbrc.2001.5874 CrossRefGoogle Scholar
  16. Felix Braga J, Ravizzoni Dartora D, Alenina N, Bader M, Santos RA (2017) Glucagon-producing cells are increased in Mas-deficient mice. Endocr Connect 6:27–32.  https://doi.org/10.1530/ec-16-0098 CrossRefGoogle Scholar
  17. Giani JF et al (2009) Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol Endocrinol Metab 296:E262–E271CrossRefGoogle Scholar
  18. Giani JF, Burghi V, Veiras LC, Tomat A, Muñoz MC, Cao G, Turyn D, Toblli JE, Dominici FP (2012) Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Ren Physiol 302:F1606–F1615CrossRefGoogle Scholar
  19. Guimaraes GG et al (2012) Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. Peptides 38:54–61.  https://doi.org/10.1016/j.peptides.2012.05.024 CrossRefGoogle Scholar
  20. Gupte M et al (2012) Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 32:1392–1399.  https://doi.org/10.1161/atvbaha.112.248559 CrossRefGoogle Scholar
  21. Gustaityte V, Winkler M, Stoelting I, Raasch W (2018) Influence of AT1 blockers on obesity and stress induced eating of cafeteria diet. J Endocrinol.  https://doi.org/10.1530/joe-18-0477
  22. He H et al (2010) Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 55:869–879.  https://doi.org/10.1161/hypertensionaha.109.143958 CrossRefGoogle Scholar
  23. Heringer-Walther S, Gembardt F, Perschel FH, Katz N, Schultheiss HP, Walther T (2012) The genetic deletion of Mas abolishes salt induced hypertension in mice. Eur J Pharmacol 689:147–153.  https://doi.org/10.1016/j.ejphar.2012.05.025 CrossRefGoogle Scholar
  24. Hrenak J, Paulis L, Simko F (2016) Angiotensin A/Alamandine/MrgD Axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 17.  https://doi.org/10.3390/ijms17071098
  25. Huber G, Schuster F, Raasch W (2017) Brain renin-angiotensin system in the pathophysiology of cardiovascular diseases. Pharmacol Res 125:72–90.  https://doi.org/10.1016/j.phrs.2017.06.016 CrossRefGoogle Scholar
  26. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM (2005) Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289:H1013–H1019CrossRefGoogle Scholar
  27. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970–976CrossRefGoogle Scholar
  28. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-Moussa N (2002) Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr 132:1135–1140.  https://doi.org/10.1093/jn/132.6.1135 CrossRefGoogle Scholar
  29. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6:12CrossRefGoogle Scholar
  30. Klein N et al (2013) Angiotensin-(1-7) protects from experimental acute lung injury. Crit Care Med 41:e334–e343.  https://doi.org/10.1097/CCM.0b013e31828a6688 CrossRefGoogle Scholar
  31. Lautner RQ et al (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112:1104–1111.  https://doi.org/10.1161/circresaha.113.301077 CrossRefGoogle Scholar
  32. Li H, Li M, Liu P, Wang YP, Zhang H, Li HB, Yang SF, Song Y, Yin YR, Gao L, Cheng S, Cai J, Tian G (2016) Telmisartan ameliorates nephropathy in metabolic syndrome by reducing leptin release from perirenal adipose tissue. Hypertension 68:478–490.  https://doi.org/10.1161/hypertensionaha.116.07008 CrossRefGoogle Scholar
  33. Liu C, Lv XH, Li HX, Cao X, Zhang F, Wang L, Yu M, Yang JK (2012) Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol 49:291–299CrossRefGoogle Scholar
  34. Miesel A, Muller-Fielitz H, Johren O, Vogt FM, Raasch W (2012) Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. Br J Pharmacol 165:2721–2735.  https://doi.org/10.1111/j.1476-5381.2011.01726.x CrossRefGoogle Scholar
  35. Montgomery MK, Hallahan NL, Brown SH, Liu M, Mitchell TW, Cooney GJ, Turner N (2013) Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. Diabetologia 56:1129–1139.  https://doi.org/10.1007/s00125-013-2846-8 CrossRefGoogle Scholar
  36. Montgomery MK, Brown SHJ, Mitchell TW, Coster ACF, Cooney GJ, Turner N (2017) Association of muscle lipidomic profile with high-fat diet-induced insulin resistance across five mouse strains. Sci Rep 7:13914.  https://doi.org/10.1038/s41598-017-14214-1 CrossRefGoogle Scholar
  37. Muller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Johren O, Raasch W (2011) Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedeberg's Arch Pharmacol 383:373–384CrossRefGoogle Scholar
  38. Muller-Fielitz H, Landolt J, Heidbreder M, Werth S, Vogt FM, Johren O, Raasch W (2012a) Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARgamma target gene regulation. Endocrinology 153:1103–1115.  https://doi.org/10.1210/en.2011-0183 CrossRefGoogle Scholar
  39. Muller-Fielitz H, Lau M, Johren O, Stellmacher F, Schwaninger M, Raasch W (2012b) Blood pressure response to angiotensin ii is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol 166:2417–2429CrossRefGoogle Scholar
  40. Muller-Fielitz H, Hubel N, Mildner M, Vogt FM, Barkhausen J, Raasch W (2014) Chronic blockade of angiotensin AT(1) receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Br J Pharmacol 171:746–760.  https://doi.org/10.1111/bph.12510 CrossRefGoogle Scholar
  41. Muller-Fielitz H, Lau M, Geissler C, Werner L, Winkler M, Raasch W (2015) Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats. Br J Pharmacol 172:857–868.  https://doi.org/10.1111/bph.12949 CrossRefGoogle Scholar
  42. Neubauer B, Schrankl J, Steppan D, Neubauer K, Sequeira-Lopez ML, Pan L, Gomez RA, Coffman TM, Gross KW, Kurtz A, Wagner C (2018) Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo? Hypertension 71:1075–1082.  https://doi.org/10.1161/hypertensionaha.117.10357 CrossRefGoogle Scholar
  43. Niu MJ, Yang JK, Lin SS, Ji XJ, Guo LM (2008) Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 34:56–61.  https://doi.org/10.1007/s12020-008-9110-x CrossRefGoogle Scholar
  44. Oliveira Andrade JM et al (2014) Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides 55:158–165.  https://doi.org/10.1016/j.peptides.2014.03.006 CrossRefGoogle Scholar
  45. Oliveira AC et al (2018) Genetic deletion of the alamandine receptor MRGD leads to dilated cardiomyopathy in mice. Am J Phys Heart Circ Phys.  https://doi.org/10.1152/ajpheart.00075.2018
  46. Pais R, Rievaj J, Larraufie P, Gribble F, Reimann F (2016) Angiotensin II type 1 receptor-dependent GLP-1 and PYY secretion in mice and humans. Endocrinology 157:3821–3831.  https://doi.org/10.1210/en.2016-1384 CrossRefGoogle Scholar
  47. Pena Silva RA, Chu Y, Miller JD, Mitchell IJ, Penninger JM, Faraci FM, Heistad DD (2012) Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke 43:3358–3363.  https://doi.org/10.1161/strokeaha.112.667063 CrossRefGoogle Scholar
  48. Qaradakhi T, Apostolopoulos V, Zulli A (2016) Angiotensin (1-7) and Alamandine: similarities and differences. Pharmacol Res 111:820–826.  https://doi.org/10.1016/j.phrs.2016.07.025 CrossRefGoogle Scholar
  49. Rabello Casali K et al (2016) Increased vascular sympathetic modulation in mice with Mas receptor deficiency. J Renin-Angiotensin-Aldosterone Syst 17:1470320316643643.  https://doi.org/10.1177/1470320316643643 CrossRefGoogle Scholar
  50. Rabelo LA et al (2016) Genetic deletion of ACE2 induces vascular dysfunction in C57BL/6 mice: role of nitric oxide imbalance and oxidative stress. PLoS One 11:e0150255.  https://doi.org/10.1371/journal.pone.0150255 CrossRefGoogle Scholar
  51. Rong X et al (2010) Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. DiabetologiaGoogle Scholar
  52. Santos RA (2014) Angiotensin-(1-7). Hypertension 63:1138–1147CrossRefGoogle Scholar
  53. Santos RA et al (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100:8258–8263.  https://doi.org/10.1073/pnas.1432869100 CrossRefGoogle Scholar
  54. Santos SH et al (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57:340–347CrossRefGoogle Scholar
  55. Santos SH et al (2010) Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 30:953–961CrossRefGoogle Scholar
  56. Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2012) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin angiotensin system. J EndocrinolGoogle Scholar
  57. Santos SH et al (2013) Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats. J Mol Med (Berl)Google Scholar
  58. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ (2018) The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 98:505–553.  https://doi.org/10.1152/physrev.00023.2016 CrossRefGoogle Scholar
  59. Schuchard J et al (2015) Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Br J Pharmacol 172:3764–3778.  https://doi.org/10.1111/bph.13172 CrossRefGoogle Scholar
  60. Schupp M et al (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442–3452CrossRefGoogle Scholar
  61. Schuster F et al (2018) Telmisartan prevents diet-induced obesity and preserves leptin transport across the blood-brain barrier in high-fat diet-fed mice. Pflugers Arch - Eur J Physiol 470:1673–1689.  https://doi.org/10.1007/s00424-018-2178-0 CrossRefGoogle Scholar
  62. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS (2007) Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28:702–707.  https://doi.org/10.1016/j.peptides.2006.10.007 CrossRefGoogle Scholar
  63. Silva AR et al (2013) Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Phys Regul Integr Comp Phys 305:R1323–R1330Google Scholar
  64. Skurk T, Lee YM, Hauner H (2001) Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37:1336–1340CrossRefGoogle Scholar
  65. Skurk T, van Harmelen V, Blum WF, Hauner H (2005) Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 13:969–973.  https://doi.org/10.1038/oby.2005.113 CrossRefGoogle Scholar
  66. Tetzner A et al (2016) G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension 68:185–194.  https://doi.org/10.1161/hypertensionaha.116.07572 CrossRefGoogle Scholar
  67. Tetzner A, Naughton M, Gebolys K, Eichhorst J, Sala E, Villacanas O, Walther T (2018) Decarboxylation of Ang-(1-7) to Ala(1)-Ang-(1-7) leads to significant changes in pharmacodynamics. Eur J Pharmacol 833:116–123.  https://doi.org/10.1016/j.ejphar.2018.05.031 CrossRefGoogle Scholar
  68. Tikellis C et al (2008) ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57:1018–1025.  https://doi.org/10.2337/db07-1212 CrossRefGoogle Scholar
  69. Tikellis C, Brown R, Head GA, Cooper ME, Thomas MC (2014) Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. Am J Physiol Ren Physiol 306:F773–F780.  https://doi.org/10.1152/ajprenal.00264.2013 CrossRefGoogle Scholar
  70. Trajcevski KE, O’Neill HM, Wang DC, Thomas MM, al-Sajee D, Steinberg GR, Ceddia RB, Hawke TJ (2013) Enhanced lipid oxidation and maintenance of muscle insulin sensitivity despite glucose intolerance in a diet-induced obesity mouse model. PLoS One 8:e71747.  https://doi.org/10.1371/journal.pone.0071747 CrossRefGoogle Scholar
  71. Uchiyama T, Okajima F, Mogi C, Tobo A, Tomono S, Sato K (2017) Alamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissue. PLoS One 12:e0178769.  https://doi.org/10.1371/journal.pone.0178769 CrossRefGoogle Scholar
  72. Vazquez-Medina JP et al (2013) Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats. Am J Physiol Heart Circ Physiol 305:H599–H607CrossRefGoogle Scholar
  73. Wang Y, Shoemaker R, Powell D, Su W, Thatcher S, Cassis L (2017) Differential effects of Mas receptor deficiency on cardiac function and blood pressure in obese male and female mice. Am J Phys Heart Circ Phys 312:H459–h468.  https://doi.org/10.1152/ajpheart.00498.2016 Google Scholar
  74. Winkler M et al (2016) The brain renin-angiotensin system plays a crucial role in regulating body weight in diet-induced obesity in rats. Br J Pharmacol 173:1602–1617.  https://doi.org/10.1111/bph.13461 CrossRefGoogle Scholar
  75. Wu HT, Chuang YW, Huang CP, Chang MH (2018) Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide. Exp Anim 67:41–49.  https://doi.org/10.1538/expanim.17-0053 CrossRefGoogle Scholar
  76. Xu P et al (2008) Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 51:574–580.  https://doi.org/10.1161/hypertensionaha.107.102764 CrossRefGoogle Scholar
  77. Yuan L, Wang Y, Lu C, Li X (2013) Angiotensin-converting enzyme 2 deficiency aggravates glucose intolerance via impairment of islet microvascular density in mice with high-fat diet. J Diabetes Res 2013:405284.  https://doi.org/10.1155/2013/405284 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Experimental and Clinical Pharmacology and ToxicologyUniversity of LübeckLübeckGermany
  2. 2.CBBM (Center of Brain, Behavior and Metabolism)LübeckGermany
  3. 3.Department for Radiology and Nuclear MedicineUniversity of LübeckLübeckGermany
  4. 4.Max-Delbrück-Center for Molecular Medicine (MDC)BerlinGermany
  5. 5.National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological SciencesFederal University of Minas GeraisBelo HorizonteBrazil
  6. 6.DZHK (German Centre for Cardiovascular Research), partner siteBerlinGermany
  7. 7.Center for Structural and Cell Biology in Medicine, Institute for BiologyUniversity of LübeckLübeckGermany
  8. 8.Charité – University Medicine BerlinBerlinGermany
  9. 9.DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/LübeckLübeckGermany

Personalised recommendations